Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) operates at the forefront of synthetic biology, combining cell programming expertise with biosecurity solutions for industries ranging from pharmaceuticals to agriculture. This news hub provides investors and industry professionals with essential updates on the company's strategic initiatives and technological advancements.
Access real-time announcements including earnings reports, R&D breakthroughs, and strategic partnerships that demonstrate Ginkgo's leadership in biological engineering. The platform serves as a comprehensive resource for tracking developments in their core Cell Engineering services and Biosecurity programs.
Discover updates on Ginkgo's AI-driven innovations, government contracts, and cross-industry collaborations that shape the future of synthetic biology. Content is curated to help stakeholders understand how biological engineering advancements translate to commercial opportunities.
Bookmark this page for streamlined access to verified financial disclosures, operational milestones, and analysis of emerging trends in cell programming technology. Regular updates ensure you stay informed about developments impacting DNA's market position and sector leadership.
Ginkgo Bioworks (NYSE: DNA) has announced a strategic partnership with Inductive Bio and Tangible Scientific to revolutionize AI-driven drug discovery workflows. The collaboration integrates three key capabilities: Ginkgo Datapoints' ADME profiling, Inductive Bio's chemistry design platform, and Tangible Scientific's compound management system.
The partnership aims to streamline the drug discovery process by combining high-throughput experimental workflows, compound management, and AI models into a unified service. Located in Boston's biopharma hub, the integrated platform offers rapid ADME profiling services including microsomal stability, kinetic solubility, P450 inhibition, and permeability testing, with optional in vitro toxicity assessments.
This collaboration supports the FDA's initiatives for faster development timelines, onshored services, increased AI tool usage, and adoption of non-animal preclinical testing approaches. The services are currently available for pharmaceutical and biotech teams.
Ginkgo Bioworks (NYSE: DNA) has appointed Brian O'Sullivan as Head of Commercial for Ginkgo Automation to accelerate external growth. O'Sullivan, formerly from HighRes Biosolutions, will oversee all revenue-generating functions including sales, business development, and marketing.
The appointment comes as Ginkgo Automation expands from internal R&D support to serving external clients with its RAC (Reconfigurable Automation Cart) hardware, Catalyst scheduling software, and remote monitoring services. O'Sullivan brings extensive experience in commercial leadership, having successfully grown HighRes's operations globally and held senior positions at Agilent Technologies, Velocity11, and Beckman Coulter.
Ginkgo Bioworks (NYSE: DNA) reported Q2 2025 financial results, with total revenue of $50 million, down from $56 million year-over-year. The company's Cell Engineering revenue grew 8% to $39 million, while Biosecurity revenue declined to $10 million. The company reported a GAAP net loss of $60 million, significantly improved from a $217 million loss in the prior year.
Notably, Ginkgo achieved its $250 million annualized cost reduction target three months ahead of schedule through workforce reductions and site consolidation. The company maintains its 2025 outlook of $167-$187 million in total revenue and aims to reach Adjusted EBITDA breakeven by the end of 2026. Ginkgo also expanded its services, launching new automated ADME profiling and cell-free protein synthesis systems.
Ginkgo Bioworks (NYSE: DNA), a leader in cell programming and biosecurity, has scheduled its Q2 2025 earnings presentation for Thursday, August 7, 2025, at 5:30 p.m. ET. The company will review its business performance for the quarter ended June 30, 2025.
Investors can access the presentation and Q&A session through Ginkgo's investor relations website. Questions can be submitted in advance via X (using #GinkgoResults) or email to investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) has secured a $4.66M contract to deploy its Reconfigurable Automation Carts (RACs) technology at the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory. The project involves constructing a fully integrated workcell with 18 different devices within a modular anaerobic chamber.
The automation platform will enable remote operation of complex anaerobic phenotyping workflows, streamlining research processes for EMSL scientists. The system features a web-based software stack with API gateway access, supporting AI-driven autonomous science capabilities. The platform is expected to be fully operational later this year, advancing research in microbial engineering and biodesign.
Ginkgo Bioworks (NYSE: DNA) has launched a new high-throughput ADME profiling service through Ginkgo Datapoints, leveraging its proprietary RAC automation technology. The service aims to accelerate small molecule drug discovery by providing cost-competitive ADME testing within the United States, matching or beating prices from international vendors, including Chinese competitors.
The service features automated workflows, rapid turnaround times, and AI-compatible datasets designed to help researchers prioritize drug candidates more efficiently. This initiative demonstrates Ginkgo's commitment to delivering affordable, high-quality services to the biopharma industry while keeping operations U.S.-based.
Ginkgo Bioworks (NYSE: DNA) announced a leadership transition as current CFO Mark Dmytruk plans to resign on May 30, 2025. Steven Coen, the company's Chief Accounting Officer, will be promoted to CFO. Coen, who joined Ginkgo in May 2023, brings over 30 years of experience in public accounting and corporate finance leadership. His previous role was Corporate VP and Controller at Charles River Laboratories, overseeing finances for a $4.0 billion revenue organization with 20,000 employees across 150 locations. The transition comes as Ginkgo works toward its goal of reaching Adjusted EBITDA breakeven by the end of 2026.
Twist Bioscience (NASDAQ: TWST) and Ginkgo Bioworks (NYSE: DNA) have revised their 2022 collaboration agreement with new terms. The updated three-year $15 million agreement maintains Ginkgo as a valued customer of Twist's DNA products with preferential pricing and no minimum purchase requirements. As part of the deal, Twist receives licenses and assignments for long DNA technology and related reagents, while Ginkgo retains rights to practice the transferred IP. The agreement involves annual prepayments from Ginkgo for Twist's DNA products.
Phytolon and Ginkgo Bioworks (NYSE: DNA) have achieved a significant milestone in their natural food colors collaboration, nearly tripling manufacturing efficiency. The partnership, initiated in 2022, focuses on developing yeast strains to produce two natural colors: "Beetroot Red" and "Prickly Pear Yellow."
This breakthrough comes amid increasing pressure to eliminate artificial food dyes in the U.S., with FDA Commissioner Marty Makary announcing plans to remove synthetic colors from the food supply by 2026. The FDA has already banned FD&C Red No. 3 due to cancer risks.
The improved production process offers significant advantages:
- Higher production efficiency (3x increase)
- Reduced production costs
- Lower carbon footprint
- Successful coloring in multiple food categories including baked goods, snacks, dairy, and confectioneries
As part of the milestone achievement, Ginkgo will receive additional equity in Phytolon, strengthening their partnership in sustainable food coloring solutions.